JPRN-jRCT2080221552未知3 期
ong-term study of SYR-472
TAKEDA PHARMACEUTICAL COMPANY LTD.0 个研究点目标入组 622 人开始时间: 2011年8月31日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 622
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •1. The subject is an outpatient.
- •2. The subject signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
排除标准
- •1. The subject has any serious cardiac disease, serious cerebrovascular disorder, or any serious pancreatic or hematological disease.
- •2. The subject is considered ineligible for the study for any other reason by the investigator or subinvestigator.
研究者
相似试验
未知
3 期
ong-term study of SYR-322Type 2 Diabetes mellitusJPRN-jRCT2080221603TAKEDA PHARMACEUTICAL COMPANY LTD.
未知
3 期
Double-blind comparative study of SYR-472Diabetes mellitusJPRN-jRCT2080221797TAKEDA PHARMACEUTICAL COMPANY LTD.
未知
2 期
A phase II dose-ranging study of SYR-472Diabetes mellitusJPRN-jRCT2080220868Takeda Pharmaceutical Company Limited
未知
3 期
ong-term study of K-877dyslipidemiaJPRN-jRCT2080222446Kowa Co., Ltd.170
未知
3 期
ong-term study of K-877DyslipidemiaJPRN-jRCT2080222362Kowa Co., Ltd.165